Navigation Links
Patent Expiries of Blockbuster Antibiotics Will Fuel a Decline of More Than 15 Percent in the Community-Acquired Pneumonia Drug Market
Date:12/8/2009

WALTHAM, Mass., Dec. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the patent expiries of three blockbuster antibiotics -- levofloxacin, moxifloxacin and piperacillin/tazobactam -- will be the primary factors contributing to a decline of more than 15 percent in the community-acquired pneumonia drug market though 2018.

The new Pharmacor report entitled Community-Acquired Pneumonia finds that generic erosion of levofloxacin (Johnson & Johnson's Levaquin, Sanofi-Aventis's Tavanic and Daiichi Sankyo's Cravit), moxifloxacin (Bayer/Merck/Shionogi's Avelox), and piperacillin/tazobactam (Pfizer's Zosyn and Taisho Toyama's Tazocin) will fuel a 1.6 percent annual decline in sales of antibiotics to treat community-acquired pneumonia. As a result, the market will decrease from more than $850 million in 2008 to more than $720 million in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Although patent expiries in both the inpatient and outpatient settings will constrain the market, the launch of several new agents in the inpatient setting will help to partially offset losses in the overall market, according to the report.

"Two of the most clinically and commercially promising antibiotics in late-stage development are Johnson & Johnson/Basilea's ceftobiprole and Forest Laboratories/AstraZeneca/Takeda's ceftaroline, which are both broad-spectrum intravenous agents with anti-MRSA activity," said Decision Resources Analyst Jacqueline Lyons, MPH. "We forecast that these two agents combined will earn nearly $100 million in the community-acquired pneumonia market in 2018."

The report also finds that the community-acquired pneumonia market is characterized by untapped commercial opportunity for new drug development in the moderate to severe setting, for the treatment of resistant pathogens with agents that do not induce resistance, and for drugs with interchangeable intravenous and oral formulations to facilitate discharge of hospitalized patients.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


For more information, contact:

Decision Resources                        Decision Resources, Inc.
Christopher Comfort                       Elizabeth Marshall
781-296-2597                              781-296-2563
ccomfort@dresources.com                   emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
2. ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx
3. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
4. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
5. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
6. Consumer Advocates Support Patent Office on Stem Cell Patent Rejection
7. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
8. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
9. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
10. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
11. New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, ... Commercialization of Public Research (the Florida Institute) ... agreement SegAna, LLC, an Orlando ... Central Florida. The Florida Institute supports new company ... funding gaps for companies spinning out of Florida-based universities ...
(Date:12/5/2016)... Dec. 5, 2016  Breckenridge Pharmaceutical, Inc. announced ... marketing agreement with development and manufacturing partner Gland ... the terms of this agreement, Breckenridge will market ... the United States . The ... ANDA. The products cover a wide range of ...
(Date:12/5/2016)... 2016  Sharn Anesthesia Inc. announced today that it ... partner for Salter Labs.  The company also received the ... of outstanding sales performance. Salter Labs is ... care, including the market gold standard ECO 2 ... of the Parker Flex-Tip® Endotracheal Tube, which is a ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... , ... “Epilepsy Awareness,” which can be found at the ... about epilepsy, bearing down on the social stigma and lack of public education ... within their lifetime. With such a large percentage of people affected, it’s critically ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, LLC (PER®) ... on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February 24, 2017. ... to have Amy E. Herman present at this year’s conference, her unprecedented knowledge ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... gender, and geographic lines. The goal of Castlewood Treatment Centers has always been ... accessible to as many people as possible. In that spirit, Castlewood has ...
(Date:12/5/2016)... ... December 05, 2016 , ... Dr. Barry M. Weintraub, one of New York ... participated in the 36th Annual Cutting Edge Aesthetic Symposium at the Waldorf Astoria in ... that perfect, yet natural-looking, nose. Dr. Weintraub, who is world-renowned for his expertise in ...
(Date:12/5/2016)... ... 2016 , ... Sideline Products is a Southern York County Pennsylvania-based premier designer ... and the horse. Smaller saddles can pinch and irritate the horse creating safety issues ... properly fitted western saddle so it does not impact the comfort or performance of ...
Breaking Medicine News(10 mins):